Infectious Diseases 🦠
https://infectiousdiseases.substack.com/
Infectious Diseases-related Inspirational Works
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections
BALANCE Investigators, Canadian Critical Care Trials Group, Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, Australian and New Zealand Intensive Care Society Clinical Trials Group, Australasian Society for Infectious Diseases Clinical Research Network, Daneman N, Rishu A, Pinto R, Rogers BA, Shehabi Y, Parke R, Cook D, Arabi Y, Muscedere J, Reynolds S, Hall R, Dwivedi DB, McArthur C, McGuinness S, Yahav D, Coburn B, Geagea A, Das P, Shin P, Detsky M, Morris A, Fralick M, Powis JE, Kandel C, Sligl W, Bagshaw SM, Singhal N, Belley-Cote E, Whitlock R, Khwaja K, Morpeth S, Kazemi A, Williams A, MacFadden DR, McIntyre L, Tsang J, Lamontagne F, Carignan A, Marshall J, Friedrich JO, Cirone R, Downing M, Graham C, Davis J, Duan E, Neary J, Evans G, Alraddadi B, Al Johani S, Martin C, Elsayed S, Ball I, Lauzier F, Turgeon A, Stelfox HT, Conly J, McDonald EG, Lee TC, Sullivan R, Grant J, Kagan I, Young P, Lawrence C, O'Callaghan K, Eustace M, Choong K, Aslanian P, Buehner U, Havey T, Binnie A, Prazak J, Reeve B, Litton E, Lother S, Kumar A, Zarychanski R, Hoffman T, Paterson D, Daley P, Commons RJ, Charbonney E, Naud JF, Roberts S, Tiruvoipati R, Gupta S, Wood G, Shum O, Miyakis S, Dodek P, Kwok C, Fowler RA
N Engl J Med, 392, 1065–1078 (2025)
Cloxacillin versus cefazolin for meticillin-susceptible Staphylococcus aureus bacteraemia (CloCeBa): a prospective, open-label, multicentre, non-inferiority, randomised clinical trial
Burdet C, Saïdani N, Dupieux C, Lemaignen A, Canouï E, Surgers L, Vareil MO, Lefort A, Lepeule R, Peiffer-Smadja N, Charmillon A, Le Moing V, Boutoille D, Tolsma V, Abgrall S, Wolff M, Tattevin P, Esposito-Farèse M, Vandenesch F, Duval X, Tubiana S, Lescure FX, CloCeBa Study Group
Lancet, 406, 2349–2359 (2025)
Efficacy, Safety, Pharmacokinetics, and Microbiome Changes of Ibezapolstat in Adults with Clostridioides difficile Infection: A Phase 2a Multicenter Clinical Trial
Garey KW, McPherson J, Dinh AQ, Hu C, Jo J, Wang W, Lancaster CK, Gonzales-Luna AJ, Loveall C, Begum K, Jahangir Alam M, Silverman MH, Hanson BM
Clin Infect Dis, 75, 1164–1170 (2022)
Cloxacillin plus fosfomycin versus cloxacillin alone for methicillin-susceptible Staphylococcus aureus bacteremia: a randomized trial
Grillo S, Pujol M, Miró JM, López-Contreras J, Euba G, Gasch O, Boix-Palop L, Garcia-País MJ, Pérez-Rodríguez MT, Gomez-Zorrilla S, Oriol I, López-Cortés LE, Pedro-Botet ML, San-Juan R, Aguado JM, Gioia F, Iftimie S, Morata L, Jover-Sáenz A, García-Pardo G, Loeches B, Izquierdo-Cárdenas Á, Goikoetxea AJ, Gomila-Grange A, Dietl B, Berbel D, Videla S, Hereu P, Padullés A, Pallarès N, Tebé C, Cuervo G, Carratalà J, SAFO study group
Nat Med, 29, 2518–2525 (2023)
Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia
Holland TL, Cosgrove SE, Doernberg SB, Jenkins TC, Turner NA, Boucher HW, Pavlov O, Titov I, Kosulnykov S, Atanasov B, Poromanski I, Makhviladze M, Anderzhanova A, Stryjewski ME, Assadi Gehr M, Engelhardt M, Hamed K, Ionescu D, Jones M, Saulay M, Smart J, Seifert H, Fowler VG Jr, ERADICATE Study Group
N Engl J Med, 389, 1390–1401 (2023)
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial
Kaasch AJ, López-Cortés LE, Rodríguez-Baño J, Cisneros JM, Dolores Navarro M, Fätkenheuer G, Jung N, Rieg S, Lepeule R, Coutte L, Bernard L, Lemaignen A, Kösters K, MacKenzie CR, Soriano A, Hagel S, Fantin B, Lafaurie M, Talarmin JP, Dinh A, Guimard T, Boutoille D, Welte T, Reuter S, Kluytmans J, Martin ML, Forestier E, Stocker H, Vitrat V, Tattevin P, Rommerskirchen A, Noret M, Adams A, Kern WV, Hellmich M, Seifert H, SABATO study group
Lancet Infect Dis, 24, 523–534 (2024)
Multi-omic profiling a defined bacterial consortium for treatment of recurrent Clostridioides difficile infection
Menon R, Bhattarai SK, Crossette E, Prince AL, Olle B, Silber JL, Bucci V, Faith J, Norman JM
Nat Med, 31, 223–234 (2025)
Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol
de Kretser D, Mora J, Bloomfield M, Campbell A, Cheng MP, Guy S, Hensgens M, Kalimuddin S, Lee TC, Legg A, Mahar RK, Marks M, Marsh J, McGlothin A, Morpeth SC, Sud A, Ten Oever J, Yahav D, Bonten M, Bowen AC, Daneman N, van Hal SJ, Heriot GS, Lewis RJ, Lye DC, McQuilten Z, Paterson DL, Owen Robinson J, Roberts JA, Scarborough M, Webb SA, Whiteway L, Tong SYC, Davis JS, Walls G, Goodman AL, SNAP Early Oral Switch Domain-Specific Working Group and SNAP Global Trial Steering Committee, SNAP Trial Group
Clin Infect Dis, 79, 871–887 (2024)
No matching items
Infectious Diseases Lab Publications
No matching items
Indications in Infectious Diseases
Clostridioides difficile Infection 🦠
No matching items
Community-Acquired Pneumonia 🫁
No matching items
Staph Bacteremia 🩸
No matching items
Invasive Fungal Infection 🍄
No matching items
Urinary Tract Infections 🚽
No matching items
Meningitis 🧠
No matching items
Endocarditis 🫀
No matching items
Osteomyelitis 🦴
No matching items